MX343968B - Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. - Google Patents

Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.

Info

Publication number
MX343968B
MX343968B MX2013010050A MX2013010050A MX343968B MX 343968 B MX343968 B MX 343968B MX 2013010050 A MX2013010050 A MX 2013010050A MX 2013010050 A MX2013010050 A MX 2013010050A MX 343968 B MX343968 B MX 343968B
Authority
MX
Mexico
Prior art keywords
lupus
delanzomib
treatment
proteasome inhibitor
subject
Prior art date
Application number
MX2013010050A
Other languages
English (en)
Other versions
MX2013010050A (es
Inventor
A Ruggeri Bruce
M Seavey Matthew
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2013010050A publication Critical patent/MX2013010050A/es
Publication of MX343968B publication Critical patent/MX343968B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención provee un método para tratamiento de lupus en un sujeto, que comprende la etapa de administrar al sujeto el compuesto A.
MX2013010050A 2011-03-03 2012-03-02 Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. MX343968B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448743P 2011-03-03 2011-03-03
PCT/US2012/027440 WO2012119056A1 (en) 2011-03-03 2012-03-02 Proteasome inhibitor delanzomib for use in the treatment of lupus

Publications (2)

Publication Number Publication Date
MX2013010050A MX2013010050A (es) 2013-11-01
MX343968B true MX343968B (es) 2016-11-30

Family

ID=45930987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010050A MX343968B (es) 2011-03-03 2012-03-02 Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.

Country Status (7)

Country Link
US (1) US9340559B2 (es)
EP (1) EP2680858A1 (es)
JP (2) JP2014506934A (es)
CA (1) CA2827653A1 (es)
MX (1) MX343968B (es)
TW (1) TW201309303A (es)
WO (1) WO2012119056A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN105705149A (zh) * 2013-10-03 2016-06-22 米伦纽姆医药公司 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CA3003741A1 (en) * 2015-11-02 2017-05-11 University Of Rochester Bortezomib conjugates and methods using same
CN117338932A (zh) * 2017-08-23 2024-01-05 科智生命科学公司 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
CN108624558A (zh) * 2018-05-16 2018-10-09 浙江省中医药研究院 一种NZW/LacJ狼疮鼠脾淋巴细胞激素耐药模型及其建立方法
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
NZ598172A (en) 2004-03-30 2013-08-30 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
DE102008019916A1 (de) 2008-04-11 2009-10-29 Reinhard Dr. Voll Verfahren zur Eliminierung von langlebigen Plasmazellen
EP2238973A1 (en) * 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
NZ596541A (en) 2009-05-27 2013-12-20 Cephalon Inc Combination therapy for the treatment of multiple myeloma using cep-18770 together with bortezomib or mephalan
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑

Also Published As

Publication number Publication date
JP2014506934A (ja) 2014-03-20
CA2827653A1 (en) 2012-09-07
TW201309303A (zh) 2013-03-01
US9340559B2 (en) 2016-05-17
MX2013010050A (es) 2013-11-01
WO2012119056A1 (en) 2012-09-07
JP2017061449A (ja) 2017-03-30
US20130345174A1 (en) 2013-12-26
EP2680858A1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
IN2014CN02887A (es)
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
WO2012106735A3 (en) Plasma-assisted skin treatment
PH12012501719A1 (en) Compounds for immunoproteasome inhibition
UA110813C2 (uk) Лікування ліподистрофії
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
IN2014CN04634A (es)
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
UA114417C2 (uk) Інгібітори iap
IN2014DN03464A (es)
WO2011083482A3 (en) Method for treatment of psoriasis
IN2014DN00254A (es)
GB201107985D0 (en) Process
PH12014502065A1 (en) Vesicular formulations
PH12014502461A1 (en) Biomarkers for iap inhibitor therapy
HUE038149T2 (hu) Eljárás acél kezelésére
AU2012240388A8 (en) Treatment regimens
MX2014006255A (es) Tratamientos neurologiocos con metaloporfirina.
MX362111B (es) Un metodo para mejorar la funcion hepatica.
GB2496723B (en) Sludge treatment process
IN2014KN01772A (es)
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
MX338595B (es) Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.

Legal Events

Date Code Title Description
FG Grant or registration